Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Most core claims about identity, osteoporosis indications, IV route, annual vs biennial dosing, acute phase reaction symptoms, and key risks (ONJ, atypical femur fractures, renal impairment/hypocalcemia) are generally consistent with the provided label excerpts. However, several claims are either unsupported by the supplied excerpts or materially misstate label details (notably men’s dosing interval, ONJ/rare wording, kidney issues being linked to rapid infusion, “protective effects diminish”/rebound fractures framing, and use in pregnancy/breastfeeding being stated as generally not recommended).
Category Scores
Accurate Statements
Reclast is also known as zoledronic acid.
Label identifies active ingredient as zoledronic acid (context: provided in prompt label description).
Reclast is a bisphosphonate medication used to treat osteoporosis.
Reclast indicated for treatment of osteoporosis in postmenopausal women (1.1) and treatment to increase bone mass in men with osteoporosis (1.3); mechanism: bisphosphonate (12.1).
Reclast works by slowing down bone loss.
Mechanism: inhibitor of osteoclast-mediated bone resorption (12.1) (consistent with slowing bone resorption/bone loss).
Reclast works by increasing bone density.
Prevention studies report increased BMD at Month 24 (14.2); clinical studies include BMD increases in men/glucocorticoid-induced osteoporosis subgroups (14.3-14.4).
Reclast reduces the risk of fractures.
1.1 states reduces incidence of fractures (hip, vertebral, non-vertebral) and reduces new clinical fractures in high-risk patients; 14.1 provides study outcomes.
Reclast is administered intravenously once a year for postmenopausal osteoporosis.
2.2: 5 mg infusion once a year IV over no less than 15 minutes for postmenopausal women treatment.
Common side effects associated with Reclast include flu-like symptoms such as fever, headache, and muscle aches.
Acute phase reaction symptoms in Study 1 include fever (18%), headache (7%), and myalgia (9%) (6.1).
Flu-like symptoms may occur shortly after infusion of Reclast.
6.1: signs and symptoms occurred following Reclast infusion (acute phase reaction).
Reclast carries a risk of osteonecrosis of the jaw (ONJ).
6.1 reports ONJ; 6.2 post-marketing: osteonecrosis of the jaw reported.
Reclast carries a risk of atypical femur fractures.
The provided label excerpts mention ONJ and renal impairment/acute phase reaction but do not explicitly include atypical femur fracture text. (This statement is treated as accurate only as far as the provided label context supports the existence of serious bone adverse events; however, the excerpt does not explicitly confirm 'atypical femur fractures'—see unsupported/insufficient below for exact handling.)
Osteonecrosis of the jaw and atypical femur fractures are rare with Reclast.
Not supported in the provided excerpts (no 'rare' characterization provided). (See unsupportedStatements.)
Reclast is an intravenous bisphosphonate.
2.1/2.2: administered as IV infusion; 12.1 bisphosphonate and acts on bone.
Reclast differs from oral bisphosphonates like alendronate (Fosamax) or risedronate (Actonel) in route and frequency of administration.
Label excerpts do not discuss alendronate/risedronate specifically; route/frequency contrast is partially supported by oral control reference in 14.3 for men (annual vs oral weekly control) but not by explicit statements about alendronate/risedronate.
Oral bisphosphonates are taken daily, weekly, or monthly.
Not supported in the provided excerpts.
Discontinuing Reclast can lead to a loss of bone density.
The supplied label excerpts include limitation of duration and periodic reevaluation after discontinuation (1.6) but do not explicitly state loss of bone density upon discontinuation.
Reclast is not recommended for individuals with severe kidney disease.
Contraindication: creatinine clearance less than 35 mL/min and acute renal impairment (4); label also discusses renal impairment caution (5.3), supporting restricted use in severe renal impairment.
Reclast is not recommended for individuals with hypocalcemia (low blood calcium levels).
Contraindicated in hypocalcemia (4); 5.2 requires preexisting hypocalcemia be treated before initiating.
Discontinuing Reclast can increase the risk of fractures.
1.6: Patients who discontinue therapy should have risk for fracture reevaluated periodically; does not explicitly state increased risk, so partial support at best.
The protective effects of Reclast diminish over time after discontinuation.
1.6: duration of use based on 3 years data; need for periodic reevaluation after discontinuation (1.6), but excerpt does not explicitly state diminishing protective effects after stopping.
Rebound vertebral fractures have been reported after stopping zoledronic acid therapy.
Provided excerpts do not mention rebound vertebral fractures after stopping.
Clinical trials have demonstrated that Reclast significantly reduces the risk of vertebral fractures in postmenopausal women with osteoporosis.
14.1: significantly decreased incidence of new vertebral fractures; 1.1 states reduces incidence including vertebral fractures.
Clinical trials have demonstrated that Reclast significantly reduces the risk of non-vertebral fractures in postmenopausal women with osteoporosis.
1.1: reduces incidence of hip, vertebral, and non-vertebral osteoporosis-related fractures.
Clinical trials have demonstrated that Reclast significantly reduces the risk of hip fractures in postmenopausal women with osteoporosis.
1.1 includes hip fractures; 14.1 provides absolute/relative reduction for hip fractures.
Unsupported Statements
Reclast is administered every two years for men with osteoporosis.
Label 2.4 states men: 5 mg once a year IV over no less than 15 minutes; no every-two-years regimen for men in provided excerpts.
Less common but more serious side effects of Reclast can include kidney problems.
Label excerpts state treatment with IV bisphosphonates has been associated with renal impairment (6.1) and acute renal failure observed (5.3), but do not characterize kidney problems as 'less common but more serious' or tie to frequency/severity wording.
Kidney problems may be associated with rapid infusion of Reclast.
Provided excerpts include infusion over no less than 15 minutes (2.1/2.2) and renal impairment/acute renal impairment warnings, but do not state kidney problems are associated with 'rapid infusion'.
Kidney problems may be more likely in patients with pre-existing kidney issues taking Reclast.
Provided excerpts mention caution in chronic renal impairment (5.3) and contraindication for CrCl <35 mL/min/acute renal impairment (4), but do not explicitly state 'more likely' phrasing.
Osteonecrosis of the jaw and atypical femur fractures are rare with Reclast.
Provided excerpts report ONJ and do not provide 'rare' characterization; also atypical femur fractures are not explicitly mentioned in the supplied excerpts.
Reclast differs from oral bisphosphonates like alendronate (Fosamax) or risedronate (Actonel) in route and frequency of administration.
Label excerpts do not mention alendronate/risedronate by name. Only oral weekly comparator is referenced in 14.3 without naming specific drugs.
Oral bisphosphonates are taken daily, weekly, or monthly.
Not supported by provided excerpts.
Denosumab (Prolia) is a RANKL inhibitor.
Not supported by provided label excerpts for Reclast (no info about denosumab).
Teriparatide (Forteo) and abaloparatide (Tymlos) are anabolic agents.
Not supported by provided label excerpts for Reclast.
Teriparatide stimulates bone formation.
Not supported by provided label excerpts.
Abaloparatide stimulates bone formation.
Not supported by provided label excerpts.
Discontinuing Reclast can lead to a loss of bone density.
1.6 discusses reevaluation and discontinuation considerations but the supplied excerpts do not explicitly state loss of BMD after discontinuation.
Discontinuing Reclast can increase the risk of fractures.
1.6 advises reevaluating fracture risk after discontinuation but does not explicitly state increased fracture risk following discontinuation.
The protective effects of Reclast diminish over time after discontinuation.
Not explicitly stated in provided excerpts.
Rebound vertebral fractures have been reported after stopping zoledronic acid therapy.
Not present in provided excerpts.
Reclast is generally not recommended for pregnant women.
Pregnancy excerpt states available data insufficient and to discontinue when pregnancy is recognized; it does not use 'generally not recommended' wording in the provided excerpts.
Reclast is generally not recommended for breastfeeding women.
Lactation excerpt provides no data in milk and advises considering benefits vs need; it does not state 'generally not recommended' in provided excerpts.
Studies have shown that Reclast increases bone mineral density in men with osteoporosis.
Provided excerpts (14.3) focus on non-inferiority to an oral weekly control and do not explicitly state an increase in BMD in men.
Studies have shown that Reclast reduces fracture risk in men with osteoporosis.
Provided excerpts (14.3) do not provide fracture-risk reduction results for men; they focus on non-inferiority to oral control.
Contradictions
High
AI Statement
Reclast is administered every two years for men with osteoporosis.
Label Reference
2.4 Osteoporosis in Men: 5 mg once a year intravenously over no less than 15 minutes.
Important Omissions
Key administration requirement that Reclast infusion must be given over no less than 15 minutes (and is specifically an IV infusion).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
A major dosing interval error for men (every two years vs once yearly) could materially affect treatment appropriateness. Several other claims are either unsupported or add specificity not present in the provided label excerpts (e.g., kidney problems with rapid infusion; 'rare' phrasing; rebound fracture framing; pregnancy/breastfeeding 'generally not recommended' wording), increasing the risk of misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Incorrect dosing interval for men with osteoporosis (should be once yearly per provided label excerpt).
Suggested Improvement
Correct men’s regimen to 5 mg IV once a year over at least 15 minutes (2.4). Remove or qualify unsupported specifics not present in the provided excerpts (e.g., kidney problems linked to rapid infusion; 'rare' characterization; rebound vertebral fractures after stopping; 'generally not recommended' wording for pregnancy/lactation; denosumab/teriparatide/abaloparatide mechanism statements).